COMPANY

Minerva Neurosciences

HQ: Burlington, MA source · minervaneurosciences.com ↗ · New England

Keywords: psychiatry schizophrenia Negative Symptoms of Schizophrenia Negative Symptoms in Schizophrenia Major Depressive Disorder MIN-101 MIN-117

Location: Burlington, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Apr 23, 2026 Trial start Phase 3: Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone a source ↗
Oct 21, 2025 Raise Private placement: $200M (up to, as announced), announced Oct 21, 2025. Source: SEC filing. source ↗
Oct 13, 2023 Trial start Phase 1: A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Sym source ↗
Mar 30, 2018 Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder source ↗
Dec 15, 2017 Trial start Phase 3: Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia source ↗
Jan 9, 2017 Trial start Phase 1: A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers source ↗
Nov 30, 2016 Trial start Phase 1: A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects source ↗
2014-09 Trial start Phase 1: Pharmacokinetic Study of MIN-101 in Healthy Subjects source ↗

2027-12 (ESTIMATED) · Phase 3 · Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antips · NCT07565428

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $200.0M. Last 2 years.

Oct 21, 2025 Private placement: $200M (up to, as announced), announced Oct 21, 2025. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07565428	Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications	Phase 3	Recruiting	Apr 23, 2026	2027-12 (estimated)
NCT06107803	A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia	Phase 1	Completed	Oct 13, 2023	Jan 12, 2024 (actual)
NCT03397134	Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia	Phase 3	Completed	Dec 15, 2017	May 26, 2020 (actual)
NCT03446846	A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder	Phase 2	Completed	Mar 30, 2018	Nov 21, 2019 (actual)
NCT03038646	A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects	Phase 1	Completed	Nov 30, 2016	Apr 20, 2017 (actual)
NCT03072056	A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers	Phase 1	Completed	Jan 9, 2017	Jul 7, 2017 (actual)
NCT02232529	Pharmacokinetic Study of MIN-101 in Healthy Subjects	Phase 1	Completed	2014-09	2015-02 (actual)